Biogen CEO Vounatsos scores $2.5M raise amid investor demands for a new strategy

Biogen CEO Vounatsos scores $2.5M raise amid investor demands for a new strategy

Source: 
Fierce Pharma
snippet: 

Biogen CEO Michel Vounatsos saw a boost in his compensation package in 2018, as the board rewarded him for record revenues. But now that the company's key pipeline asset has failed, Vounatsos is under pressure to come up with a new R&D plan.